Justin Renz was named Chief Financial Officer of Zevra Therapeutics, Inc., effective March 9, 2026. As of November 14, 2026, Zevra Therapeutics, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on March 9, 2026, naming 1 appointment (Form 8-K, March 9, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like Zevra Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Zevra Therapeutics, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-03-09. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Zevra Therapeutics, Inc. files it.
Also on the record for Zevra Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 5, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 9.4% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Woodline Partners LP | 8.1% of the class | 5%+ stakes | Source |
| August 6, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 8.3% of the class | 5%+ stakes | Source |
| July 31, 2026 | Stake report, Schedule 13G, by Vanguard Capital Management | 5.11% of the class | 5%+ stakes | Source |
| May 6, 2026 | Stake report, Schedule 13G, by FMR LLC | 5.5% of the class | 5%+ stakes | Source |
| March 27, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by Woodline Partners LP | 6.2% of the class | 5%+ stakes | Source |
| November 13, 2025 | Stake report, Schedule 13G/A, by Adage Capital Management, L.P. | 3.96% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Zevra Therapeutics, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Zevra Therapeutics, Inc. and the records around it.
Zevra Therapeutics, Inc. elsewhere on the record
Companies that share a holder
- Woodline Partners LP also filed stake reports on 19 other companies: Biohaven Ltd. (Aug 2026), Black Rock Coffee Bar, Inc. (Aug 2026), CalciMedica, Inc. (Aug 2026)
- Adage Capital Management, L.P. also filed stake reports on 161 other companies: Ares Acquisition Corp III (Nov 2026), Avidbank Holdings, Inc. (Nov 2026), B&R Technology Merger Corp. (Nov 2026)
- FMR LLC also filed stake reports on 762 other companies: ASPEN NEUROSCIENCE INC (Nov 2026), AVALO THERAPEUTICS INC (Nov 2026), BRAZE INC (Nov 2026)
Watch Zevra Therapeutics, Inc.
Get an email when Zevra Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Zevra Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Zevra Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Zevra Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
9 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-03-09 | In | Chief Financial Officer | 2026-03-09 | 8-K, 2026-03-09 |
Who leads Zevra Therapeutics, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Financial Officer: Justin Renz, appointed, effective 2026-03-09 (filed 2026-03-09).
New leaders reset buying decisions — get the Full Report on Zevra Therapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Financial Officer at Zevra Therapeutics, Inc., with the record behind each one.
Find candidates like Chief Financial Officer at Zevra Therapeutics, Inc.Every change, in the filing's words
Appointed: Justin Renz, Chief Financial Officer, effective 2026-03-09
On March 4, 2026, the Company appointed Justin Renz as Chief Financial Officer and Treasurer, effective March 9, 2026, and as principal financial officer, effective March 10, 2026.
- Beginning in 2017, Mr. Renz held various positions of increasing responsibility at Correvio Pharma Corp, a specialty pharmaceutical company, most recently as its President and Chief Financial Officer at the time of its acquisition by Advanz Pharma in May 2020.
- From 2014 to 2017, Mr. Renz was the Executive Vice President and Chief Financial Officer of Karyopharm Therapeutics, Inc. Prior to that, from 2006 to 2014, Mr. Renz held a variety of financial positions with Zalicus Pharmaceuticals Ltd., a biopharmaceutical company, including most recently as Executive Vice President and Chief Financial Officer at the time of its acquisition by Epirus Biopharmaceuticals, Inc. in 2014.
- In connection with his employment, Mr. Renz and the Company have entered into an employment agreement (the "Employment Agreement") effective as of March 9, 2026.
- Under the Employment Agreement, his annualized base salary will be $520,000.
- Mr. Renz will be eligible to receive an annual performance bonus with a bonus target of 45% of his annual base salary.
- Mr. Renz will also receive an option to purchase 300,000 shares of the Company's common stock (the "Equity Award") pursuant to and in accordance with the terms and conditions of Company's Amended and Restated 2023 Employment Inducement Award Plan.
Tools for this story
Each opens in a new tab, filled in for Zevra Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
